Sonic Healthcare Selects Translational Software’s Pharmacogenomics Platform to Advance Precision Medicine in Australia
Jul. 10, 2018
BELLEVUE, Wash.--(BUSINESS WIRE)--Jul 10, 2018--Translational Software®, Inc. (TSI), a global leader in the intelligent use of genetic data for clinical decision support, has finalized an agreement with Sonic Genetics, a member of Sonic Healthcare, one of the world’s largest medical diagnostics companies, to provide pharmacogenomic (PGx) decision support for lab testing services in Australia. PGx testing assesses an individual’s genomic markers to predict clinical response to specific medications to help clinicians more closely tailor personalized treatment.
Sonic Genetics chose to partner with TSI based on its robust knowledge-base of actively curated, evidence-based PGx content. TSI’s proprietary knowledge platform provides flexible reporting, genomic decision support and critical alerts regarding drug efficacy, toxicity and known interactions to guide clinical decision-making and enable physicians to prescribe the most effective medications. With clinical reporting for 65 genes, TSI’s PGx platform can be tailored to a variety of clinical specialties including cardiovascular, psychiatric, pain, internal medicine and geriatrics. Most importantly, TSI’s platform is rigorously curated and continually updated to prevent alert fatigue by only surfacing information that has the highest levels of evidence.
Sonic Genetics is at the forefront of providing comprehensive genetic testing services, offering thousands of genetic tests to support the optimal management of patient care, with laboratories across Australia, UK, Europe and USA. “We are pleased to extend our genetic testing services with Translational Software’s PGx platform to help clinicians ensure more precise patient treatment,” stated Dr. Colin Goldschmidt, CEO and managing director at Sonic Healthcare Limited. “We look forward to collaborating with a leading genomic data pioneer like TSI to offer the widest range of genetic testing services possible for our clients in Australia to advance the adoption of precision medicine and improve healthcare outcomes.”
TSI’s solutions empower customers to offer scalable and cost-effective precision medicine services. In addition to the most comprehensive and flexible PGx reporting solution available, the company offers an API that enables software providers to quickly expand their applications with PGx-based knowledge. With this powerful foundation, TSI is aligning with industry thought leaders such as Sonic Healthcare to help bring PGx closer to the point of care.
“Expanding the availability of PGx testing for clinicians is an essential first step for ensuring the integration of precision medicine into clinical practice,” stated Don Rule, CEO of TSI. “We are excited to work with Sonic Healthcare to help inform safer and more effective treatment decisions for its customers and their patients in Australia.”
About Sonic Healthcare:
Sonic Healthcare ( www.sonichealthcare.com.au ) is an international medical diagnostics company, offering extensive laboratory medicine/pathology and radiology services to the medical community. With 33,000 employees around the world, Sonic Healthcare is recognised for quality and service excellence, innovative technology, commitment to staff and continuing financial strength. Sonic Healthcare is represented in Australia, New Zealand, United Kingdom, Germany, Switzerland, Belgium, Ireland and the USA. The global head office of Sonic Healthcare is in Sydney, Australia.
About Translational Software, Inc.
Translational Software enables healthcare providers to realize the promise of precision medicine. We simplify complex genetic data into evidence-based actionable recommendations to deliver genomic decision support in platform agnostic formats. Our PGx knowledge base and Fast Healthcare Interoperability Resource (FHIR)-based API has been used to provide over one million PGx recommendations. To learn more visit us at www.TranslationalSoftware.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180710005271/en/
CONTACT: Myla Wagner Public Relations for Translational Software, Inc.
Myla Wagner, 925-736-7515
KEYWORD: AUSTRALIA UNITED STATES NORTH AMERICA AUSTRALIA/OCEANIA WASHINGTON
INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE PRACTICE MANAGEMENT HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS PHARMACEUTICAL
SOURCE: Translational Software®, Inc
Copyright Business Wire 2018.
PUB: 07/10/2018 09:00 AM/DISC: 07/10/2018 09:01 AM